June 28, 2017
Clinicians report improved surgical workflow, patient comfort
and accuracy in stereotactic imaging and treatment
Elekta (EKTA-B.ST) today announced that its
Leksell®Vantage™ Stereotactic System is now in clinical use at three European
centers. The first surgeries were performed on a patient with Parkinson's
disease at the National Hospital for Neurology and Neurosurgery, Queen
Square (London, England) and a patient with Parkinson's disease at
Karolinska University Hospital (Stockholm, Sweden). Both sites have now treated
several patients.
Subsequent to these first two procedures,
Academisch Medisch Centrum (Amsterdam, the Netherlands) has also initiated
clinical use of Vantage. Additionally, Hopital La Timone (Marseille, France)
has completed training on Vantage and is commencing system utilization.
Leksell Vantage is Elekta's next-generation
system for target localization and coordinate referencing during stereotactic
neurosurgical procedures. Both patients were successfully implanted with deep
brain stimulation electrodes, a procedure that requires precision targeting.
Stereotactic neurosurgery is a minimally-invasive
approach to precisely localize and treat specific regions in the brain while
sparing surrounding healthy tissue. This surgery has been used successfully for
decades to treat a variety of brain and neurologic conditions, including brain
cancer, non-malignant tumors, essential tremor and Parkinson's disease.
Stereotactic neurosurgery is also used to make small controlled lesions of
brain pathologies or to facilitate drug delivery to regions of the brain that
are challenging to access. Immobilization of the patient's head during
neuroimaging and subsequent neurosurgical procedures is essential for accurate
targeting and optimal clinical safety and efficacy.
Leksell Vantage Stereotactic System was
designed with the patient in mind and to meet the most exacting demands of
today's clinicians, enabling a smooth workflow and offering a range of
benefits, including shorter treatment times, non-metallic MRI-compatible
accessories, intuitive setup and workflow enhancements.
"Our first experiences with the Leksell
Vantage Stereotactic System indicate the potential for obtaining images with
more anatomical detail," said Ludvic Zrinzo, MD, PhD, FRCS,
Senior Lecturer and Consultant in Neurosurgery at National Hospital for
Neurology and Neurosurgery, Queen Square, London.
"The 'open face' design is an advantage in both awake and
asleep surgery and the updated design provides a more patient and
user friendly system."
Prof. Lars Leksell, the founder of
Elekta, developed his innovative center-of-arc-based stereotactic system during
his tenure as professor and chairman of neurosurgery at Karolinska University
Hospital. This system ultimately evolved into a user-friendly and
world-renowned stereotactic system that has helped improve the care and
outcomes for patients around the world.
"Elekta is proud to report that the first
successful surgeries with the Leksell Vantage System have been performed at
these prestigious and experienced centers of neurosurgery. Vantage is the most
current representation of our legacy of innovation and it reflects our ongoing
commitment to working closely with clinicians to develop devices and software
that enable them to provide optimal care to all their patients," said
Jesper Söderqvist, Vice President Neuro Portfolio at Elekta.
For more information about Leksell Vantage,
stop by Elekta booth 11-13 at the 17th Quadrennial Meeting of the World
Society for Stereotactic and Functional Neurosurgery (WSSFN) or visit www.elekta.com/Vantage.
For further information, please contact:
Gert van Santen,
Group Vice President
Corporate Communications,
Elekta AB
Tel: +31-653-561-242
Time zone: CET: Central
European Time
Raven Canzeri,
Global Public Relations
Manager,
Elekta
Tel: +1-770-670-2524
Time zone: ET: Eastern Time
http://www.prnewswire.com/news-releases/parkinsons-disease-patients-are-first-to-be-treated-with-elektas-new-leksell-vantage-stereotactic-system-300480944.html
~~~~~~~~~
Elekta Highlights Leksell Vantage System
for Stereotactic Neurosurgery at AANS 2017
New studies also reinforce Gamma Knife as a
clinically effective, minimally invasive approach to treating cancer,
noncancerous brain tumors and neurological conditions
April 24, 2017 — Elekta
announced that its Leksell Vantage Stereotactic System, will be highlighted at
the American Association of Neurological Surgeons (AANS) Annual Meeting, April
22-26 in Los Angeles.
Leksell Vantage is the company's next-generation system
for target localization and coordinate referencing for precision neurosurgery.
The system’s head frame is constructed of a novel epoxy composite and is
designed to improve imaging quality, speed and patient comfort in neurosurgery
procedures.
Vantage received CE Mark clearance in March 2017 and will be used
in April in clinical practice for the first time in Europe at four centers,
including:
University Hospital La Timone (Marseilles, France);
The Academic
Medical Center (Amsterdam, the Netherlands);
The National Hospital for
Neurology and Neurosurgery, Queens Square (London, England); and Karolinska
University Hospital (Stockholm, Sweden).
The system is currently pending 510(k)
clearance with the U.S. Food and Drug Administration (FDA).
In addition to
Vantage, Elekta will highlight its Leksell Gamma Knife radiosurgery system. The
system will be discussed in more than 15 scientific presentations at AANS, including:
Abstract #1837: "Stereotactic Radiosurgery for Intractable Tremor-Dominant
Parkinson Disease"; Ajay Niranjan, M.D., MBA, associate professor,
neurological surgery, director UPMC Brain Mapping Center and associate
director, Center for Image-Guided Neurosurgery at the University of Pittsburgh
Medical Center. This study analyzed the outcomes of 33 patients who received
Gamma Knife radiosurgery to treat medically refractory Parkinson's disease (PD)
tremor. At a mean follow-up period of 23 months, 23 patients (70 percent) had
complete or nearly complete tremor arrest, and nine (27.2 percent) experienced
tremor arrest and improved ability to write, draw and drink fluids. Tremor
resolution was maintained in 96.8 percent of individuals at last follow-up visit.
Study investigators concluded that Gamma Knife is a safe and effective
treatment for medically refractory PD tremor, especially in the elderly or
individuals who are not suitable candidates for deep brain stimulation or
thermal therapy.
Abstract #2022: "Direct Comparison of Microsurgery and
Gamma Knife Radiosurgery on Small Size Meningiomas"; Shyamal C. Bir, M.D.,
Ph.D., post-doctoral fellow, Louisiana State University Health Sciences Center
Shreveport, and Anil Nanda, M.D., MPH, professor and chairman of the Department
of Neurosurgery at LSU Health Sciences Center at Shreveport. In this study,
investigators performed a retrospective review of 90 consecutive patients with
small intracranial meningiomas (benign tumors arising from the membranes covering
the brain and spinal cord) undergoing microsurgery (n= 31) or Gamma Knife
radiosurgery (n=59). Study results demonstrated that Gamma Knife radiosurgery
was associated with significantly higher local control of tumor growth compared
with microsurgical resection at five and 10 years (p=0.02 and p=0.003,
respectively). In addition, the median recurrence free survival period was also
significantly higher in the Gamma Knife group (p=0.04).
Additional data
presented during the conference confirmed that Leksell Gamma Knife was the most
frequently mentioned stereotactic radiosurgery (SRS) system in a comprehensive
clinical literature review with 11,638 citations out of 13,539 articles
retrieved. Gamma Knife was also the most frequently cited SRS system in neurosurgical
indications, including brain metastases (n=1037), arteriovenous malformation
(n=734) and spinal metastases (n=184). For more information: www.elekta.com
https://www.itnonline.com/content/elekta-highlights-leksell-vantage-system-stereotactic-neurosurgery-aans-2017
No comments:
Post a Comment